文献速递妇科

塞利尼索联合每周紫杉醇治疗转移性实体瘤患者:一项开放标签、单中心、多臂1b期研究及卵巢癌扩展期结果

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-11-21

这项开放标签、单中心、多臂1b期研究采用「3+3」设计,在复发性实体瘤中评估口服塞利尼索(60 mg或80 mg每周两次)联合每周紫杉醇(80 mg静脉注射,用药2周停1周)的最大耐受剂量和II期推荐剂量。35例可评估毒性,31例可评估疗效;未观察到剂量限制性毒性,因长期耐受性选择60 mg为II期推荐剂量。卵巢癌可评估患者24例,缓解率17%,临床获益率58%,中位无进展生存期6.8个月(95%CI 3.7至未达到)。

要点

  • 塞利尼索联合每周紫杉醇未观察到剂量限制性毒性,60 mg被选为II期推荐剂量。
  • 97%患者至少发生1例治疗中出现的不良事件,≥3级最常见为中性粒细胞减少46%、贫血31%、恶心21%。
  • 卵巢癌可评估患者24例,缓解率17%,临床获益率58%,中位无进展生存期6.8个月(95%CI 3.7至未达到)。

核心结论

  • 口服塞利尼索联合每周紫杉醇显示出有前景的临床活性且毒性可控,作者认为应考虑在随机研究中进一步探索该联合方案,尤其在卵巢恶性肿瘤中。

研究设计与样本

  • 开放标签、单中心、多臂1b期研究,采用「3+3」设计并在复发性实体瘤中进行「篮子型」扩展。
  • 塞利尼索(60 mg或80 mg每周两次口服)联合每周紫杉醇(80 mg静脉注射,用药2周停1周)为13个平行臂之一。
  • 35例患者可评估毒性,31例(88%)可评估疗效;患者诊断为铂耐药/难治性卵巢癌(n=28)、乳腺癌(n=4)、前列腺癌(n=2)和宫颈癌(n=1)。
  • 患者既往中位治疗线数为4线(范围1-10),47%在复发阶段接受过紫杉烷类治疗。

主要发现

  • 未观察到剂量限制性毒性,因长期耐受性选择60 mg为II期推荐剂量。
  • 97%患者至少发生1例治疗中出现的不良事件,≥3级最常见不良事件为中性粒细胞减少(46%)、贫血(31%)和恶心(21%)。
  • 卵巢癌可评估患者24例中,缓解率为17%,临床获益率为58%,中位无进展生存期为6.8个月(95%CI 3.7至未达到)。

关键数值与推荐

  • 卵巢癌可评估患者24例,缓解率17%,临床获益率58%,中位无进展生存期6.8个月(95%CI 3.7至未达到)。

临床怎么用

  • 作者认为口服塞利尼索联合每周紫杉醇显示出有前景的临床活性且毒性可控,应考虑在随机研究中进一步探索,尤其在卵巢恶性肿瘤中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound which blocks Exportin-1 (XPO1). Our objective was to determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of selinexor and weekly paclitaxel. METHODS: This was an open label, single-center, multi-arm phase 1b study utilizing a "3 + 3" design and a "basket-type" expansion in recurrent solid tumors. Selinexor (60 mg or 80 mg twice weekly orally) and weekly paclitaxel (80 mg IV 2 week on, 1 week off) were one of 13 parallel arms. Efficacy was evaluated using RECIST version 1.1. RESULTS: All 35 patients treated were evaluable for toxicity and 31 (88%) were evaluable for response. Patient diagnoses included platinum-resistant/refractory ovarian (n = 28), breast (n = 4), prostate (n = 2), and cervical (n = 1) cancer. Patients had a median of four prior therapies (range 1-10), and 47% had a prior taxane in the recurrent setting. There were no DLTs and 60 mg was chosen as the RP2D due to long-term tolerability. Ninety-seven percent of patients had at least one treatment-emergent adverse event (TEAE), and the most common grade ≥ 3 TEAE were neutropenia (46%), anemia (31%), and nausea (21%). Among 24 evaluable patients with ovarian cancer, response rate was 17%, CBR was 58%, and median PFS was 6.8 months (95% CI 3.7, not reached (NR)). CONCLUSIONS: Oral selinexor in combination with weekly paclitaxel demonstrated promising clinical activity with manageable toxicity. This combination should be considered for further exploration in a randomized study, especially in ovarian malignancies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Westin SN, Fu S, Tsimberidou A, et al. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2022. PMID: 36423446. doi:10.1016/j.ygyno.2022.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。